All articles tagged with #venous thromboembolism
A NEJM trial comparing apixaban (Eliquis) and rivaroxaban (Xarelto) found Eliquis had a lower risk of clinically relevant bleeding in patients with venous thromboembolism, with similar efficacy in preventing recurrent clots; however, results may not generalize beyond a largely white, healthy population, suggesting Eliquis could be a safer first-line option for many patients.
COBRRA (2760 patients, 3 months) shows apixaban reduces clinically relevant bleeding vs rivaroxaban in acute VTE (3.3% vs 7.1%), with major and clinically relevant nonmajor bleeding also lower (0.4% vs 2.4%; 2.9% vs 4.9%), while recurrent symptomatic VTE is similar (~1%). The safety edge could shift guidelines and insurer preference toward apixaban, though the study’s short follow-up and predominantly White population are limitations; a COBRA-AF trial in atrial fibrillation is planned.
A comprehensive U.S. study involving over 6,500 adults has linked long-term exposure to air pollution with an increased risk of venous thromboembolism (VTE), a condition involving blood clots in deep veins. The study, funded by the NIH, found that exposure to fine particulate matter and nitrogen oxides significantly raised the risk of VTE, which can lead to serious health complications. The research highlights the impact of air pollution on cardiovascular health, emphasizing the need for public health measures to reduce exposure.